RU2008129364A - Новые циклически замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний - Google Patents
Новые циклически замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний Download PDFInfo
- Publication number
- RU2008129364A RU2008129364A RU2008129364/04A RU2008129364A RU2008129364A RU 2008129364 A RU2008129364 A RU 2008129364A RU 2008129364/04 A RU2008129364/04 A RU 2008129364/04A RU 2008129364 A RU2008129364 A RU 2008129364A RU 2008129364 A RU2008129364 A RU 2008129364A
- Authority
- RU
- Russia
- Prior art keywords
- carbon atoms
- alkyl
- group
- formula
- amino
- Prior art date
Links
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical class C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 title claims abstract 10
- 208000024172 Cardiovascular disease Diseases 0.000 title claims 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 52
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 18
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 14
- -1 1H-tetrazol-5-yl Chemical group 0.000 claims abstract 13
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 13
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000012453 solvate Substances 0.000 claims abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 12
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 11
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 7
- 125000002252 acyl group Chemical group 0.000 claims abstract 6
- 125000004442 acylamino group Chemical group 0.000 claims abstract 6
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 6
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims abstract 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 4
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 131
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- 239000001301 oxygen Substances 0.000 claims 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 10
- 239000011737 fluorine Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 229920002554 vinyl polymer Chemical group 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 102000009079 Epoprostenol Receptors Human genes 0.000 abstract 2
- 108091006335 Prostaglandin I receptors Proteins 0.000 abstract 2
- CBIWCJGTVQGGIQ-UHFFFAOYSA-N 2-[3-[[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino]phenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC=CC=2)OC2=NC=NC(NC=3C=C(OCC(O)=O)C=CC=3)=C12 CBIWCJGTVQGGIQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 230000003257 anti-anginal effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000002439 hemostatic effect Effects 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000001525 receptor binding assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005061171.0 | 2005-12-21 | ||
| DE102005061171A DE102005061171A1 (de) | 2005-12-21 | 2005-12-21 | Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008129364A true RU2008129364A (ru) | 2010-01-27 |
Family
ID=37758644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129364/04A RU2008129364A (ru) | 2005-12-21 | 2006-12-08 | Новые циклически замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8324222B2 (enExample) |
| EP (1) | EP1966218B1 (enExample) |
| JP (1) | JP2009523711A (enExample) |
| KR (1) | KR20080081325A (enExample) |
| CN (1) | CN101384602A (enExample) |
| AT (1) | ATE473982T1 (enExample) |
| AU (1) | AU2006334855A1 (enExample) |
| BR (1) | BRPI0620647A2 (enExample) |
| CA (1) | CA2633698A1 (enExample) |
| DE (2) | DE102005061171A1 (enExample) |
| ES (1) | ES2347593T3 (enExample) |
| IL (1) | IL192081A0 (enExample) |
| RU (1) | RU2008129364A (enExample) |
| WO (1) | WO2007079861A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007019690A1 (de) * | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
| DE102007027800A1 (de) * | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
| DE102007051762A1 (de) * | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
| DE102007054786A1 (de) * | 2007-11-16 | 2009-05-20 | Bayer Healthcare Ag | Trisubstituierte Furopyrimidine und ihre Verwendung |
| KR101314508B1 (ko) * | 2008-08-25 | 2013-10-07 | 듀퐁 일렉트로닉 폴리머스 엘피 | 신규한 프로파노에이트 및 그의 제조 방법 |
| EP4255893A4 (en) * | 2020-12-04 | 2025-04-23 | The Johns Hopkins University | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROPATHIC PAIN |
| CN115462369B (zh) * | 2022-09-29 | 2023-09-22 | 安徽省立医院(中国科学技术大学附属第一医院) | 一种玻璃化冷冻外泌体保存方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3577420A (en) * | 1968-01-05 | 1971-05-04 | Pfizer | Certain 4-aminofuro(2,3-d)pyrimidines |
| ES2219033T3 (es) | 1998-07-22 | 2004-11-16 | Daiichi Suntory Pharma Co., Ltd. | Inhibidores de nf-kappa b que contienen derivados de indano como ingrediente activo. |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| WO2001021206A1 (en) | 1999-09-17 | 2001-03-29 | Suntory Limited | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-λB INHIBITORS AS THE ACTIVE INGREDIENT |
| CA2449188A1 (en) | 2001-05-14 | 2002-11-21 | Novartis Ag | Oxazolo-and furopyrimidines and their use in medicaments against tumors |
| DE10141212A1 (de) * | 2001-08-22 | 2003-03-06 | Bayer Ag | Neue 4-Aminofuropyrimidine und ihre Verwendung |
| AU2002333524A1 (en) | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
| US20030225098A1 (en) * | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
| KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제 |
| CA2568304A1 (en) | 2004-06-10 | 2005-12-22 | Xention Discovery Limited | Furanopyrimidine compounds effective as potassium channel inhibitors |
| JP2008505084A (ja) | 2004-06-29 | 2008-02-21 | アムゲン インコーポレイティッド | フラノピリミジン |
-
2005
- 2005-12-21 DE DE102005061171A patent/DE102005061171A1/de not_active Withdrawn
-
2006
- 2006-12-08 AT AT06840964T patent/ATE473982T1/de active
- 2006-12-08 CA CA002633698A patent/CA2633698A1/en not_active Abandoned
- 2006-12-08 US US12/086,784 patent/US8324222B2/en not_active Expired - Fee Related
- 2006-12-08 RU RU2008129364/04A patent/RU2008129364A/ru not_active Application Discontinuation
- 2006-12-08 DE DE502006007450T patent/DE502006007450D1/de active Active
- 2006-12-08 AU AU2006334855A patent/AU2006334855A1/en not_active Abandoned
- 2006-12-08 KR KR1020087017645A patent/KR20080081325A/ko not_active Withdrawn
- 2006-12-08 WO PCT/EP2006/011825 patent/WO2007079861A1/de not_active Ceased
- 2006-12-08 CN CNA200680053205XA patent/CN101384602A/zh active Pending
- 2006-12-08 JP JP2008546192A patent/JP2009523711A/ja active Pending
- 2006-12-08 EP EP06840964A patent/EP1966218B1/de not_active Not-in-force
- 2006-12-08 ES ES06840964T patent/ES2347593T3/es active Active
- 2006-12-08 BR BRPI0620647-6A patent/BRPI0620647A2/pt not_active IP Right Cessation
-
2008
- 2008-06-12 IL IL192081A patent/IL192081A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0620647A2 (pt) | 2011-11-16 |
| KR20080081325A (ko) | 2008-09-09 |
| EP1966218A1 (de) | 2008-09-10 |
| EP1966218B1 (de) | 2010-07-14 |
| ES2347593T3 (es) | 2010-11-02 |
| US20110124665A1 (en) | 2011-05-26 |
| IL192081A0 (en) | 2008-12-29 |
| JP2009523711A (ja) | 2009-06-25 |
| US8324222B2 (en) | 2012-12-04 |
| DE502006007450D1 (de) | 2010-08-26 |
| CA2633698A1 (en) | 2007-07-19 |
| CN101384602A (zh) | 2009-03-11 |
| ATE473982T1 (de) | 2010-07-15 |
| AU2006334855A1 (en) | 2007-07-19 |
| DE102005061171A1 (de) | 2007-07-05 |
| WO2007079861A1 (de) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11401259B2 (en) | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | |
| RU2744988C2 (ru) | Соединения и композиции для подавления активности shp2 | |
| AU2014219283C1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| CA2529686C (en) | 2-acylaminothiazole derivative or salt thereof | |
| EP3310774A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| WO2016203405A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| EP3094629A1 (en) | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 | |
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| RU2007149317A (ru) | Циклическое производное амина, содержащее замещенную алкильную группу | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| WO2016089060A2 (en) | Heterocyclic derivatives and use thereof | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| JP2021518379A5 (enExample) | ||
| JP2020525490A (ja) | ヘテロアリールジヒドロピリミジン誘導体及びｂ型肝炎感染を治療する方法 | |
| AR037350A1 (es) | Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, y uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea) | |
| IL192081A0 (en) | Novel, cyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases | |
| ES2271230T3 (es) | Derivados de isoxazolina como antidepresivos. | |
| UY28688A1 (es) | Derivados de amida | |
| RU2010141578A (ru) | Производные (пиразолилкарбонил)имидазолидинона, предназначенные для лечения ретровирусных заболеваний | |
| RU2005131735A (ru) | Химические соединения | |
| RU2007125661A (ru) | Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина | |
| RU2006109566A (ru) | Пиразолопиридины и их аналоги | |
| RU2005125636A (ru) | Производные бензоксазола и их применение в качестве лигандов рецептора аденозина | |
| RU2003130062A (ru) | Бициклические производные гуанидина и их терапевтическое использование |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100908 |